Fig. 2: Clinical characterisation of subtypes within MYCN non-amplified neuroblastomas identifies key distinguishing features. | British Journal of Cancer

Fig. 2: Clinical characterisation of subtypes within MYCN non-amplified neuroblastomas identifies key distinguishing features.

From: Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

Fig. 2

Graphs showing the frequency (%) of each molecular subtype in different International Neuroblastoma Staging System (INSS) stages or risk status in either train (a) or test (b) cohort. P values are indicated. Kaplan−Meier plots showing the overall survival in each molecular subtype or MYCN-amplification (MYCN-AMP) in either train (c) or test (d) cohort. The numbers below are n (%). P values are indicated. e Multivariate analysis of subgroup classification with risk status in MYCN non-amplified neuroblastomas. HR (hazard ratio), 95% CI (confidence interval), patient number (n), and P values are shown. f Prediction error curves (indicating a mean squared error in predicting survival status) are calculated for the subgroup (red) and INSS stage (green).

Back to article page